Free Trial
NASDAQ:DWTX

Dogwood Therapeutics Q1 2023 Earnings Report

Dogwood Therapeutics logo
$5.54 -0.13 (-2.21%)
Closing price 03:59 PM Eastern
Extended Trading
$5.45 -0.09 (-1.54%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dogwood Therapeutics EPS Results

Actual EPS
-$2.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Dogwood Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dogwood Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Thursday, May 11, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Dogwood Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Friday, May 9, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Dogwood Therapeutics Earnings Headlines

Dogwood receives Nasdaq confirmation of compliance
"I'm risking my reputation on this"
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free.
Dogwood management to meet with Maxim
See More Dogwood Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email.

About Dogwood Therapeutics

Dogwood Therapeutics (NASDAQ:DWTX) is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

View Dogwood Therapeutics Profile

More Earnings Resources from MarketBeat